keyword
https://read.qxmd.com/read/38536576/bruton-tyrosine-kinase-inhibition-an-effective-strategy-to-manage-waldenstr%C3%A3-m-macroglobulinemia
#1
REVIEW
Reema K Tawfiq, Jithma P Abeykoon, Prashant Kapoor
PURPOSE OF REVIEW: The treatment of Waldenström macroglobulinemia (WM) has evolved over the past decade. With the seminal discoveries of MYD88 and CXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) mutations in WM cells, our understanding of the disease biology and treatment has improved. The development of a new class of agents, Bruton tyrosine kinase inhibitors (BTKi), has substantially impacted the treatment paradigm of WM. Herein, we review the current and emerging BTKi and the evidence for their use in WM...
March 27, 2024: Current Hematologic Malignancy Reports
https://read.qxmd.com/read/38529117/retention-rate-of-biologic-and-targeted-synthetic-anti-rheumatic-drugs-in-elderly-rheumatoid-arthritis-patients-data-from-gisea-registry
#2
JOURNAL ARTICLE
Andreina Manfredi, Marco Fornaro, Chiara Bazzani, Simone Perniola, Alberto Cauli, Alessandra Rai, Ennio Giulio Favalli, Serena Bugatti, Maurizio Rossini, Rosario Foti, Fabrizio Conti, Giuseppe Lopalco, Anna Scalvini, Cristina Garufi, Mattia Congia, Roberto Gorla, Elisa Gremese, Fabiola Atzeni, Roberto Caporali, Florenzo Iannone, Marco Sebastiani
OBJECTIVES: An increased number of elderly individuals affected by rheumatoid arthritis (RA) has been reported, including both patients with RA onset in advanced age and patients aged with the disease. In this registry-based study, we aimed to analyze the retention rate and cause of discontinuation of biologic (b) and targeted synthetic (ts)-disease-modifying anti-rheumatic drugs (DMARDs) in RA patients over 65 year old. METHODS: RA patients enrolled in the Italian GISEA registry and starting a b- or a ts-DMARD over 65 years of age were included...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38521835/outcome-differences-by-sex-in-oncology-clinical-trials
#3
JOURNAL ARTICLE
Ashwin V Kammula, Alejandro A Schäffer, Padma Sheila Rajagopal, Razelle Kurzrock, Eytan Ruppin
Identifying sex differences in outcomes and toxicity between males and females in oncology clinical trials is important and has also been mandated by National Institutes of Health policies. Here we analyze the Trialtrove database, finding that, strikingly, only 472/89,221 oncology clinical trials (0.5%) had curated post-treatment sex comparisons. Among 288 trials with comparisons of survival, outcome, or response, 16% report males having statistically significant better survival outcome or response, while 42% reported significantly better survival outcome or response for females...
March 23, 2024: Nature Communications
https://read.qxmd.com/read/38520607/additional-data-in-expanded-patient-populations-and-new-indications-support-the-practice-of-biosimilar-to-biosimilar-switching
#4
JOURNAL ARTICLE
Hillel P Cohen, Wolfram Bodenmueller
As of 31 December, 2023, 31 observational studies have been published, including a total of 6081 patients who underwent a switch from one biosimilar to another biosimilar of the same reference biologic. Most studies evaluated infliximab, while a smaller number evaluated adalimumab, rituximab or etanercept. Indications studied now include sarcoidosis, as well as the indications previously reported of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis and inflammatory bowel disease (Crohn's disease and ulcerative colitis)...
March 23, 2024: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://read.qxmd.com/read/38505446/a-pathology-experience-of-posttransplant-lymphoproliferative-disorder-from-one-tertiary-hospital-pathology-concepts-and-diagnostic-approach
#5
JOURNAL ARTICLE
Haneen Al-Maghrabi, Bayan Hafiz, Abdelrazak Meliti
BACKGROUND: Solid organ transplantation and bone marrow/hematologic stem cell transplantation recipients face a heightened risk of developing malignancies or cancer as a result of immunosuppression. Posttransplant lymphoproliferative disorders (PTLD) are a range of disorders from benign lymphoid growth to lymphoma found post-transplant. Risk factors for PTLD include high immunosuppressive use and oncogenic effects of Epstein-Barr virus (EBV). There is a lack of comprehensive clinical and pathological documentation of PTLD cases among Saudi patients, and the available data are limited to a few case reports...
February 2024: Curēus
https://read.qxmd.com/read/38499817/the-interplay-of-rheumatoid-arthritis-and-osteoporosis-exploring-the-pathogenesis-and-pharmacological-approaches
#6
REVIEW
Nikhil Gupta, Navjot Kanwar, Anchal Arora, Kavin Khatri, Abhinav Kanwal
Rheumatoid arthritis (RA) and osteoporosis are two chronic disorders that are often seen together. RA is an autoimmune disorder that causes pain and inflammation in the joints, while osteoporosis is a disorder in which the bones become weak and fragile. Risk factors for bone loss in RA include disease activity, longer disease duration, erosive disease, autoantibody positivity, and joint damage leading to impaired physical activity. Recent research has shown that there is a complex interplay between immune cells, cytokines, and bone remodeling processes in both RA and osteoporosis...
March 18, 2024: Clinical Rheumatology
https://read.qxmd.com/read/38493059/soho-state-of-the-art-updates-and-next-questions-treatment-evolution-of-mantle-cell-lymphoma-navigating-the-different-entities-and-biological-heterogeneity-of-mantle-cell-lymphoma-in-2024
#7
REVIEW
Andrew Ip, Alexandra Della Pia, Andre H Goy
Progress in mantle cell lymphoma (MCL) has led to significant improvement in outcomes of patients even in the real world (RW) setting albeit to a lesser degree. In parallel to the demonstration of benefit using combination therapy with rituximab plus high-dose cytarabine (R-AraC) as well as dose intensive therapy-autologous stem cell transplantation (DIT-ASCT) consolidation and maintenance, it became clear over the last 2 decades that MCL is a highly heterogenous disease at the molecular level, explaining differences observed in clinical behavior and response to therapy...
February 22, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38492438/ferroptosis-mechanisms-and-its-novel-potential-therapeutic-targets-for-dlbcl
#8
REVIEW
Wenxia Bian, Haoran Li, Yuhan Chen, Yanhua Yu, Guojie Lei, Xinyi Yang, Sainan Li, Xi Chen, Huanjuan Li, Jing Yang, Chen Yang, Yanchun Li, Yi Zhou
Diffuse large B-cell lymphoma (DLBCL), a heterogeneous lymphoid malignancy, poses a significant threat to human health. The standard therapeutic regimen for patients with DLBCL is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), with a typical cure rate of 50-70%. However, some patients either relapse after complete remission (CR) or exhibit resistance to R-CHOP treatment. Therefore, novel therapeutic approaches are imperative for managing high-risk or refractory DLBCL. Ferroptosis is driven by iron-dependent phospholipid peroxidation, a process that relies on the transition metal iron, reactive oxygen species (ROS), and phospholipids containing polyunsaturated fatty acids-containing phospholipids (PUFA-PLs)...
April 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38487009/mimotope-peptide-modified-pompon-mum-like-magnetic-microparticles-for-precise-recognition-capture-and-biotransformation-analysis-of-rituximab-in-biological-fluids
#9
JOURNAL ARTICLE
Jiawen Yang, Aixuan Zhou, Minyi Li, Qiaoxian He, Jingwei Zhou, Jacques Crommen, Wentao Wang, Zhengjin Jiang, Qiqin Wang
Due to low immobilized ligand density, limited binding capacity, and severe interference from serum proteins, developing ideal peptide-based biomaterials for precise recognition and in vivo analysis of biopharmaceuticals remains a huge challenge. In this study, mimotope peptide modified pompon mum-like biomimetic magnetic microparticles (MMPs, 3.8 μm) that mimic the specific functionalities of CD20 on malignant B cells were developed for the first time. Benefit from the numerous ligand binding sites (Ni2+ ) on the pompon mum-like MMPs, these novel materials achieved ≥10 times higher peptide ligand densities (>2300 mg/g) and antibody binding capacities (1380 mg/g) compared to previous reported biomaterials...
March 2024: Acta Pharmaceutica Sinica. B
https://read.qxmd.com/read/38470360/repurposing-of-rituximab-biosimilars-to-treat-b-cell-mediated-autoimmune-diseases
#10
REVIEW
Agata Mostkowska, Guy Rousseau, Noël J-M Raynal
Rituximab, the first monoclonal antibody approved for the treatment of lymphoma, eventually became one of the most popular and versatile drugs ever in terms of clinical application and revenue. Since its patent expiration, and consequently, the loss of exclusivity of the original biologic, its repurposing as an off-label drug has increased dramatically, propelled by the development and commercialization of its many biosimilars. Currently, rituximab is prescribed worldwide to treat a vast range of autoimmune diseases mediated by B cells...
March 15, 2024: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://read.qxmd.com/read/38466527/intravenous-cyclophosphamide-therapy-for-patients-with-severe-ocular-inflammatory-diseases-who-failed-other-immunomodulatory-therapies
#11
JOURNAL ARTICLE
Irmak Karaca, Elaine M Tran, SungWho Park, Albert Bromeo, Hassan Khojasteh, Anh Ngọc Tram Tran, Negin Yavari, Amir Akhavanrezayat, Cigdem Yasar, Gunay Uludag Kirimli, Ngoc Tuong Trong Than, Muhammad Hassan, Christopher Or, Hashem Ghoraba, Diana V Do, Quan Dong Nguyen
BACKGROUND: Ocular inflammatory diseases, including scleritis and uveitis, have been widely treated with immunomodulatory therapies (IMTs) as a steroid-sparing approach. Such strategy includes conventional therapies (antimetabolites, alkylating agents, and calcineurin inhibitors) as well as biologic agents like adalimumab, infliximab, rituximab, and tocilizumab. Cyclophosphamide (CP) is an alkylating agent and mainly inhibits the functioning of both T and B cells. Though known to have potential adverse events, including bone marrow suppression, hemorrhagic cystitis, and sterility, CP has been shown to be efficacious, especially in recalcitrant cases and when used intravenous (IV) for a limited period...
March 11, 2024: Journal of Ophthalmic Inflammation and Infection
https://read.qxmd.com/read/38452297/cancer-risk-with-tocilizumab-sarilumab-abatacept-and-rituximab-treatment-in-patients-with-rheumatoid-arthritis-a-danish-cohort-study
#12
JOURNAL ARTICLE
Rasmus Westermann, René Lindholm Cordtz, Kirsten Duch, Lene Mellemkjaer, Merete Lund Hetland, Bergur Magnussen, Lene Dreyer
OBJECTIVES: To investigate cancer risk in rheumatoid arthritis (RA) patients treated with tocilizumab/sarilumab, abatacept, or rituximab compared with those who received tumour necrosis factor inhibitors (TNFi) and compared with biological disease-modifying anti-rheumatic drugs (bDMARD) naïve RA patients. METHODS: Nationwide registry-based cohort study of RA patients initiating treatment with tocilizumab/sarilumab, abatacept, rituximab, TNFi, and bDMARD-naive patients their second type of conventional synthetic DMARD (csDMARD)...
March 7, 2024: Rheumatology
https://read.qxmd.com/read/38446533/satisfaction-and-effectiveness-of-switching-from-intravenous-to-subcutaneous-belimumab-treatment-in-daily-clinical-practice
#13
JOURNAL ARTICLE
Beatriz Frade-Sosa, Tarek Carlos Salman-Monte, Javier Narváez, Irene Peralta, Sebastian Sandoval, Berta Magallares, Sergi Heredia, Nuria Sapena, Anne Riveros-Frutos, Alejandro Olivé, Hector Corominas, Josefina Cortés-Hernández, José A Gómez-Puerta
BACKGROUND: In 2017, belimumab (BEL) was approved in subcutaneous (SQ) administration. The effectiveness after switching from intravenous (IV) to SQ and patient satisfaction in daily clinical practice has not been studied. During the pandemic, patient follow-up and treatment were significantly affected, and some patients need a change from IV to SQ. Our aim was to evaluate daily clinical practice satisfaction to SQ BEL therapy in patients previously treated IV BEL. We hypothesized that SQ BEL in SLE patients previously treated with IV BEL was similar in effectiveness and conferred higher satisfaction...
March 6, 2024: Lupus
https://read.qxmd.com/read/38441463/the-serological-immunogenicity-of-the-third-and-fourth-doses-of-covid-19-vaccine-in-patients-with-inflammatory-rheumatic-diseases-on-different-biologic-or-targeted-dmards-a-swedish-nationwide-study-covid-19-reuma
#14
JOURNAL ARTICLE
Martina Frodlund, Per Nived, Katerina Chatzidionysiou, Anna Södergren, Eva Klingberg, Monica Hansson, Sophie Ohlsson, Elisa Pin, Anders Bengtsson, Lars Klareskog, Meliha Kapetanovic
UNLABELLED: Studies investigating the immunogenicity of additional COVID-19 vaccine doses in immunosuppressed patients with inflammatory rheumatic diseases (IRD) are still limited. The objective was to explore the antibody response including response to omicron virus subvariants (sBA.1 and sBS.2) after third and fourth COVID-19 vaccine doses in Swedish IRD patients treated with immunomodulating drugs compared to controls. Antibody levels to spike wild-type antigens (full-length protein and S1) and the omicron variants sBA...
March 5, 2024: Microbiology Spectrum
https://read.qxmd.com/read/38423571/infliximab-rescue-therapy-in-a-case-of-severe-granulomatous-colitis-associated-with-rituximab-use
#15
JOURNAL ARTICLE
Pablo Martinez Perez, Luke Hanna, Eleanor Jaynes, Markus Gwiggner
Colitis occurs in about 4% of individuals treated with rituximab. Optimal management of rituximab-induced colitis, which does not improve with cessation of the drug and supportive care alone, is poorly defined due to limited evidence. Severe refractory disease can lead to colectomy. We present a case of suspected rituximab-induced colitis occurring in a woman in her 70s suffering from rheumatoid arthritis. The patient achieved full clinical, endoscopic and histological remission of colitis with infliximab therapy...
February 29, 2024: BMJ Case Reports
https://read.qxmd.com/read/38406549/atypical-meningeal-localization-of-classical-hairy-cell-leukemia-with-an-impressive-response-to-rituximab-and-cladribine-association-a-case-report-and-literature-review
#16
Fabien Claves, Sylvain Carras, Barbara Burroni, Elsa Maitre, Jean Boutonnat, Xavier Troussard, Lysiane Molina
Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder classically presenting with cytopenia and recurrent infections but atypical manifestations such as bone lesions, skin lesions and effusion have been described. We report here an unusual meningeal localization in a 33 years old man who presented with headache, hand paresthesia and visual symptoms. Brain magnetic resonance imaging revealed an occipital meningeal lesion. Diagnostic explorations led to the diagnosis of classical HCL with meningeal localization...
February 2024: EJHaem
https://read.qxmd.com/read/38399463/integrating-nanotechnological-advancements-of-disease-modifying-anti-rheumatic-drugs-into-rheumatoid-arthritis-management
#17
REVIEW
Sukhbir Singh, Neha Tiwary, Neelam Sharma, Tapan Behl, Anita Antil, Md Khalid Anwer, Seema Ramniwas, Monika Sachdeva, Gehan M Elossaily, Monica Gulati, Shreesh Ohja
Disease-modifying anti-rheumatic drugs (DMARDs) is a class of anti-rheumatic medicines that are frequently prescribed to patients suffering from rheumatoid arthritis (RA). Methotrexate, sulfasalazine, hydroxychloroquine, and azathioprine are examples of non-biologic DMARDs that are being used for alleviating pain and preventing disease progression. Biologic DMARDs (bDMARDs) like infliximab, rituximab, etanercept, adalimumab, tocilizumab, certolizumab pegol, and abatacept have greater effectiveness with fewer adverse effects in comparison to non-biologic DMARDs...
February 14, 2024: Pharmaceuticals
https://read.qxmd.com/read/38399365/nk-cell-levels-correlate-with-disease-activity-in-patients-with-multiple-sclerosis-on-ocrelizumab-rituximab-therapy
#18
JOURNAL ARTICLE
Simone Dal Bello, Simone Lorenzut, Emma Saccomano, Yan Tereshko, Gian Luigi Gigli, Carlo Ennio Pucillo, Mariarosaria Valente
BACKGROUND: Recently, research on the pathogenesis of multiple sclerosis (MS) has focused on the role of B lymphocytes and the possibility of using specific drugs, such as Ocrelizumab and Rituximab, directed toward these cells to reduce inflammation and to slow disease progression. OBJECTIVE: We aimed to evaluate the effect of Ocrelizumab/Rituximab on laboratory immune parameters and identify the predictors of treatment responses. METHODS: A retrospective single-center study was conducted among patients who received infusion therapy with an anti-CD20 drug to treat MS...
January 23, 2024: Pharmaceuticals
https://read.qxmd.com/read/38396839/current-understanding-of-immune-thrombocytopenia-a-review-of-pathogenesis-and-treatment-options
#19
REVIEW
Alina Mititelu, Minodora-Cezarina Onisâi, Adrian Roșca, Ana Maria Vlădăreanu
The management of immune thrombocytopenia (ITP) and the prediction of patient response to therapy still represent a significant and constant challenge in hematology. ITP is a heterogeneous disease with an unpredictable evolution. Although the pathogenesis of ITP is currently better known and its etiology has been extensively studied, up to 75% of adult patients with ITP may develop chronicity, which represents a significant burden on patients' quality of life. A major risk of ITP is bleeding, but knowledge on the exact relationship between the degree of thrombocytopenia and bleeding symptoms, especially at a lower platelet count, is lacking...
February 10, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38368147/looking-to-achieve-cure-the-first-time-around-for-dlbcl-patients-who-are-older-and-or-with-co-morbidities
#20
JOURNAL ARTICLE
Elizabeth A Brem, Laurie H Sehn
Diffuse large B-cell lymphoma (DLBCL) is an aggressive but often curable malignancy. Older patients, especially those 80 years and older, have poor outcomes compared to those < 60, likely due to a number of reasons including disease biology, comorbidities, and treatment intolerance. Prospective data informing the treatment of older patients and those with multiple co-morbidities is limited. Here, we intend to review available data for regimens other than standard R-CHOP (rituximab, cyclophosphamide, adriamycin, prednisone) or R-pola-CHP (rituximab, polatuzumab vedotin [pola], cyclophosphamide, adriamycin, prednisone), tools available that may aid in treatment selection, and future directions, including the incorporation of newer treatment modalities into therapy for more vulnerable patients...
January 22, 2024: Seminars in Hematology
keyword
keyword
159843
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.